Effects of teriparatide on bone in autochthonous transgenic model mice for diabetes mellitus (Akita mice).
Akita mouse
Bone mineral density
Bone quality
Bone strength
Diabetes mellitus
Teriparatide
Journal
Osteoporosis and sarcopenia
ISSN: 2405-5263
Titre abrégé: Osteoporos Sarcopenia
Pays: Netherlands
ID NLM: 101666399
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
24
06
2019
revised:
10
11
2019
accepted:
23
11
2019
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
16
1
2020
Statut:
ppublish
Résumé
The purpose of this study is to evaluate the effects of teriparatide (TPTD) on bone mineral density (BMD), bone strength, and bone quality in Akita mouse models of diabetes mellitus. Twelve-week-old female Akita mice and control mice (C57/BL/6NCrSlc) were divided into 4 groups: control mice treated with vehicle (n = 7) or TPTD (n = 6); and Akita mice treated with vehicle (n = 6) or TPTD (n = 7). TPTD or vehicle was administered subcutaneously 3 times a week for 8 weeks. Blood glucose, serum sclerostin, total tibial BMD, femoral shaft bone strength, and bone quality using Fourier-transform infrared spectroscopy imaging were evaluated. No significant differences in serum sclerostin levels were evident among these groups after 8 weeks of treatment. TPTD significantly increased BMD in control mice (+12.7%, P = 0.02) and Akita mice (+29.2%, P = 0.001) compared with vehicle. Maximum load and stiffness were significantly higher in Akita mice treated with TPTD than in Akita mice treated with vehicle (+56.6%, P = 0.03 and + 90.5%, P = 0.02, respectively). On Fourier-transform infrared spectroscopy imaging, the mineral/matrix ratio was significantly lower in Akita mice treated with vehicle than in control mice (-12.2%, P = 0.02), and TPTD treatment significantly increased the mineral/matrix ratio (P = 0.003). TPTD thus improved BMD and bone strength in both control mice and Akita mice, with improvements in the mineral/matrix ratio among Akita mice.
Identifiants
pubmed: 31938729
doi: 10.1016/j.afos.2019.11.003
pii: S2405-5255(19)30080-9
pmc: PMC6953529
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109-115Informations de copyright
© 2019 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.
Déclaration de conflit d'intérêts
Naohisa Miyakoshi has received consulting fees from Asahi Kasei Pharma Corporation. The other authors have no conflicts of interest to declare.
Références
Calcif Tissue Int. 2006 Sep;79(3):160-8
pubmed: 16969591
J Clin Endocrinol Metab. 2012 May;97(5):1737-44
pubmed: 22399511
Ann N Y Acad Sci. 2010 Mar;1192:437-43
pubmed: 20392270
Bone. 2012 Nov;51(5):920-8
pubmed: 22910579
Acta Diabetol. 2009 Jun;46(2):119-26
pubmed: 18843446
J Bone Miner Res. 2001 Sep;16(9):1665-73
pubmed: 11547836
Bone. 2008 Apr;42(4):606-15
pubmed: 18280232
J Biol Chem. 2011 Mar 18;286(11):9787-96
pubmed: 21239498
J Clin Endocrinol Metab. 2012 Jan;97(1):234-41
pubmed: 22031520
J Clin Endocrinol Metab. 2012 Apr;97(4):1277-84
pubmed: 22337915
PLoS One. 2012;7(4):e33942
pubmed: 22496773
Biophys J. 1991 Oct;60(4):786-93
pubmed: 1660314
Bone Miner. 1988 Jan;3(3):193-9
pubmed: 3207944
Osteoporos Int. 2007 Apr;18(4):427-44
pubmed: 17068657
Endocrinology. 1997 Nov;138(11):4607-12
pubmed: 9348185
Osteoporos Int. 2011 Aug;22(8):2373-83
pubmed: 20959962
Am J Epidemiol. 2007 Sep 1;166(5):495-505
pubmed: 17575306
Bone. 2003 Jul;33(1):108-14
pubmed: 12919705
N Engl J Med. 2001 May 10;344(19):1434-41
pubmed: 11346808
Endocrinology. 1986 Oct;119(4):1786-92
pubmed: 3530724
J Clin Endocrinol Metab. 2008 Sep;93(9):3484-9
pubmed: 18593769
Curr Osteoporos Rep. 2008 Jun;6(2):72-6
pubmed: 18778567
J Bone Miner Res. 2000 May;15(5):944-51
pubmed: 10804025
J Orthop Res. 2004 May;22(3):457-64
pubmed: 15099621
Cell Cycle. 2009 Dec 15;8(24):4179-81
pubmed: 19946218
Endocr Rev. 2005 Aug;26(5):688-703
pubmed: 15769903
J Vet Med Sci. 2012 Jan;74(1):103-5
pubmed: 21869570
J Clin Endocrinol Metab. 2005 Aug;90(8):4644-9
pubmed: 15914535
J Cell Biochem. 2007 Dec 15;102(6):1343-57
pubmed: 17975793
J Bone Miner Res. 2001 Oct;16(10):1821-8
pubmed: 11585346
Nat Med. 2013 Feb;19(2):179-92
pubmed: 23389618
J Cell Physiol. 2012 Apr;227(4):1326-34
pubmed: 21604269
Osteoporos Int. 2006 Oct;17(10):1514-23
pubmed: 16770520
Diabetes. 1997 May;46(5):887-94
pubmed: 9133560
J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45
pubmed: 20164296
J Bone Miner Res. 2006 Feb;21(2):274-82
pubmed: 16418783
Osteoporos Int. 2010 Feb;21(2):195-214
pubmed: 19760059
Cell. 2010 Jul 23;142(2):296-308
pubmed: 20655470